Low prevalence and disease severity of COVID‐19 in post‐liver transplant recipients—A single centre experience
Open Access
- 17 June 2020
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 40 (8), 1972-1976
- https://doi.org/10.1111/liv.14552
Abstract
Coronavirus disease 2019 (COVID‐19) caused by a novel coronavirus called severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) is driving a present day global pandemic. Immunosuppressed patients are regarded as a high risk cohort. The following is a short report on COVID‐19 in liver transplant recipients (n=5) from a high volume UK liver transplant unit with a large follow up cohort (n=4500). Based on this limited data, liver transplant recipients appear to have a low incidence of COVID‐19, with less severe symptoms than expected, when compared to the general population and other solid organ recipients. This possibly could be related to self‐isolation adherence and/or the “ideal” level of immunosuppression that favourably modulates the immune response to COVID‐19.This publication has 14 references indexed in Scilit:
- Coronaviruses and Immunosuppressed Patients: The Facts During the Third EpidemicLiver Transplantation, 2020
- COVID-19 pathophysiology: A reviewClinical Immunology, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaThe New England Journal of Medicine, 2020
- Effective treatment of severe COVID-19 patients with tocilizumabProceedings of the National Academy of Sciences of the United States of America, 2020
- Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver diseaseMetabolism, 2020
- Global Transplantation COVID Report March 2020Transplantation, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Suppression of Coronavirus Replication by Cyclophilin InhibitorsViruses, 2013
- Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506Virus Research, 2012